Australia's most trusted
source of pharma news
Thursday, 12 March 2026
Posted 12 March 2026 PM
US government agency, the Advanced Research Projects Agency for Health (ARPA-H) has injected $21 million into Seaport Therapeutics and Monash University’s project to develop the first oral therapeutic for restoring gut lymphatic function.
Neuroscience-focused SeaPort Therapeutics was launched by PureTech Health in 2024 to progress the Glyph platform licensed from Monash University researchers in 2017.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.